Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Nolan, Jason M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S229000
Reexamination Certificate
active
07863307
ABSTRACT:
An efficient process is disclosed for producing a compound that is an inhibitor of CETP. The last step of the process is the coupling of an oxazolidinone derivative with a biphenyl moiety to provide a compound of formula (I). In a specific embodiment of this synthesis, a crystalline product is produced which is characterized as a non-solvated crystalline polymorph.
REFERENCES:
patent: WO 2006/014357 (2006-02-01), None
patent: WO 2006/014413 (2006-02-01), None
Okamoto et al. Nature Jul. 13, 2000, 406, 203-207.
Schafer et al. (Drug Discovery Today 2008, 13 (21/22), 913-916).
Horig et al. Journal of Translational Medicine 2004, 2(44).
Cote Aaron S.
Miller Ross A.
Daniel Mark R.
McGinnis James L.
Nolan Jason M
LandOfFree
Process for synthesizing a CETP inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for synthesizing a CETP inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for synthesizing a CETP inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731745